X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.
Lead Product(s): ATT001
Therapeutic Area: Oncology Product Name: ATT001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.
Lead Product(s): ATT001
Therapeutic Area: Oncology Product Name: ATT001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
177Lu-OPS201 (satoreotide) is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer.
Lead Product(s): 68Ga-satoreotide Trizoxetan,177Lu-satoreotide Tetraxetan
Therapeutic Area: Oncology Product Name: SSO120
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent glioblastoma.
Lead Product(s): ATD-001
Therapeutic Area: Oncology Product Name: ATD-001
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Theragnostics
Deal Size: $44 million Upfront Cash: $2.5 million
Deal Type: Acquisition June 01, 2023
Details:
Under the collaboration, UCB’s proprietary mRNA-display platform, ExtremeDiversity™ and Ariceum’s expertise in radiopharmaceuticals & labelling technology will enable discovery of peptide-radioisotope conjugates as potential therapeutics for immune-related diseases and cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undislcosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 10, 2023
Details:
The proceeds from the financing will enable Ariceum to further develop its lead asset and proprietary peptide derivative, 177Lu-OPS201 (satoreotide). Satoreotide is a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor.
Lead Product(s): Satoreotide Tetraxetan
Therapeutic Area: Oncology Product Name: 177Lu-OPS201
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: HealthCap
Deal Size: $26.4 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
